Drug Profile
Research programme: S6 kinase 1 inhibitors - Sentinel Oncology
Alternative Names: FS 115; p70S6 inhibitors - Sentinel; p70S6K1 inhibitor - Sentinel; S6K1 inhibitors - SentinelLatest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Sentinel Oncology
- Class Small molecules
- Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Triple negative breast cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in United Kingdom (PO)
- 02 Dec 2016 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Breast cancer presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
- 09 Aug 2016 Preclinical trials in Triple negative Breast cancer in United Kingdom (PO)